KARD

Conviction 0HealthcareScan · Fri, Sep 25, 2026

Kardigan, Inc. (KARD) closed at $14.78 (+2.71%) on Sep 25, 2026. Price is below its 50-day. RSI(14) 30, -42.9% from its 52-week high, -32.8% year to date. Sector: Healthcare · Biotechnology.

KARD$14.78+2.71%

ResistanceSupportVol 14Insider buy

Vol MA14 1.05M

Jun 29Jul 16Aug 4Aug 20Sep 9Sep 25

Kardigan, Inc.Biotechnology

Price14.78

Change+2.71%

Gap+2.08%

Rel volume0.87×

Avg volume816.93K

Avg $ vol14.1M

SMA 2018.32

SMA 5019.94

SMA 200—

Price vs 50-25.89%

Price vs 200—

MA stack—

50/200 cross—

Supertrenddown · 18.51

RSI (14)30

MACD hist-0.42

MACD cross—

Stoch %K / %D12 / 8

ADX (14)19

+DI / −DI18 / 29

RSI divergence—

MACD divergenceBearish

ATR %10.00%

ADR %8.03%

52w high25.90

52w low14.39

From 52w high-42.93%

Above 52w low+2.71%

New 52w highNo

SqueezeOff

Bollinger width49.55%

%B0.11

Donchian pos11.76%

Donchian high22.51

Donchian low13.75

AVWAP (52w high)19.71

vs AVWAP high-25.03%

AVWAP (52w low)14.49

vs AVWAP low+1.97%

OBV trendDown

Chaikin MF (20)-0.03

Today vs 20d0.87×

Avg vol (14d)1.05M

Avg vol (20d)816.93K

Avg $ vol (20d)14.1M

Market cap1.38B

RS Rating—

RS 3m (vs SPY)-43.18%

RS 6m (vs SPY)—

RS line new highNo

Trend template—

Technical rank5.8

1 week-11.18%

1 month-30.22%

3 months-37.37%

6 months—

1 year—

YTD-32.82%

P/E—

P/B2.25

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current8.72

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target42.25

Target upside185.86%

Analyst ratingBuy

Institutional61.19%

Ent. value997.98M

Revenue0

Net income-116.24M

Gross profit—

Free cash flow—

IndustryBiotechnology

ExchangeNasdaq

Shares out—

Employees—

Listed—

Free float51.76M

Float %55.4%

Short interest2.21M

Days to cover9.1d

Short volume86.0%

Squeeze score54 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$2.88 vs −$0.65

Last surprise-343.1% miss

Setup gradeD

Conviction0 / 100

Pattern quality—

Tech rank5.8 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance23.02

Support17.64

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in KARD

All disclosures →

No recent disclosed trades by Congress in KARD. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in KARD · open-market 2 buys

Insider	Side	Shares	Value	Traded	Filed
PERCEPTIVE ADVISORS LLC Director · Common Stock · 2026-06-17	Grant	20.71K	—	2026-06-17	2026-07-13
BERNS PAUL L Director · Common Stock · 2026-06-22	Buy	1.25M	$20M	2026-06-22	2026-06-24
ARCH Venture Partners XIII, LLC Director · Common Stock · 2026-06-22	Buy	1.25M	$20M	2026-06-22	2026-06-24
GIANAKAKOS ANASTASIOS President & CEO · Series A Preferred Stock · 2026-06-17	Convert	25.74K	—	2026-06-17	2026-06-22
GIANAKAKOS ANASTASIOS President & CEO · Series B Preferred Stock · 2026-06-17	Convert	313.09K	—	2026-06-17	2026-06-22
HRTG GPE, LLC 10% owner · Series A Redeemable Convertible Preferred Stock · 2026-06-17	Convert	3.86M	—	2026-06-17	2026-06-22
BERNS PAUL L Director · Common Stock · 2026-06-17	Convert	13.79M	—	2026-06-17	2026-06-22
GIANAKAKOS ANASTASIOS President & CEO · Series A Preferred Stock · 2026-06-17	Convert	18.02K	—	2026-06-17	2026-06-22
Walbert Timothy P Director · Common Stock · 2026-06-17	Grant	20.71K	—	2026-06-17	2026-06-22
GIANAKAKOS ANASTASIOS President & CEO · Common Stock · 2026-06-17	Convert	28.7K	—	2026-06-17	2026-06-22

SEC filings

EDGAR filings in KARD · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.